BofA still bullish on Bio-Reference Labs despite Q4 outlook

BofA is out with a cautiously bullish note on Bio-Reference Labs (BRLI -2.1%) on the heels of the company's pre-announcement late last month.

"While we are maintaining our Buy rating ... we are now modelling a weaker H1 2014 EPS outlook on lower near term profit forecasts and relying on a stronger H2 2014 experience," analyst Robert Willoughby says, lowering his price target by a dollar to $33.

From last month: BRLI slumps after guidance update

From other sites
Comments (1)
  • dowjobber
    , contributor
    Comments (206) | Send Message
    Willoughby has been behind the curve on
    Bio-Ref for the past three years. Last year
    year he loved it at 30 and the stock fell off the
    cliff and the stock fell 25%. The year before that
    the stock went down to $12 and he was neutral
    and he never even bothered to be on the quarterly
    calls (he had his assistant do it!) and missed most
    of the stellar move from $12 to $30. I don't
    see this guy doing anything but react.
    14 Dec 2013, 09:37 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs